Supplementary Data — Bromhexine for COVID-19: real-time meta-analysis of 7 studies

October 2026

Bromhexine COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlDose (1d)Relative Risk
Ansarin (RCT)91%0.09 · 0.01–1.59death0/395/3924mg Ansarin (RCT)89%0.11 · 0.01–0.84ventilation1/399/3924mg Ansarin (RCT)82%0.18 · 0.04–0.77ICU2/3911/3924mg Vila Méndez (RCT)67%0.33 · 0.01–7.94oxygen0/981/9348mg Vila Méndez (RCT)67%0.33 · 0.01–7.94hosp.0/981/9348mg Vila Méndez (RCT)71%0.29 · 0.03–2.68no recov.1/523/4548mg Vila Méndez (RCT)−187%2.87 · 0.12–68.64no recov.1/520/4548mg Vila Méndez (RCT)−7%1.07 · 0.64–1.77viral load98 (n)93 (n)48mg Vila Méndez (RCT)17%0.83 · 0.41–1.66viral load98 (n)93 (n)48mg Vila Méndez (RCT)−41%1.41 · 0.71–2.80viral load98 (n)93 (n)48mg Vila Méndez (RCT)13%0.87 · 0.68–1.11viral+52/9857/9348mg Vila Méndez (RCT)−14%1.14 · 0.94–1.37viral+73/9861/9348mg Li (RCT)75%0.25 · 0.06–1.00no disch.2/124/696mg Li (RCT)50%0.50 · 0.09–2.73oxygen2/122/696mg Mareev (RCT)11%0.89 · 0.65–1.22no recov.33 (n)33 (n)32mgCT1 Mareev (RCT)39%0.61 · 0.14–0.97no recov.14/2420/2132mgCT1 Mareev (RCT)8%0.92 · 0.77–1.09hosp. time33 (n)33 (n)32mgCT1 Mareev (RCT)87%0.13 · 0.01–2.25viral+0/173/1332mgCT1 Tolouian (RCT)76%0.24 · 0.01–8.03death48 (n)52 (n)32mg Tolouian (RCT)76%0.24 · 0.01–7.69no improv.48 (n)52 (n)32mg Tolouian (RCT)−75%1.75 · 1.13–2.71viral+29/4818/5232mg Mikhaylov (RCT)80%0.20 · 0.01–3.97hosp.0/252/2524mg Mikhaylov (RCT)91%0.09 · 0.01–1.56symp. case0/255/2524mg Mikhaylov (RCT)71%0.29 · 0.07–1.24cases2/257/2524mg Tolouian (DB RCT)33%0.67 · 0.04–10.46death0/1871/18524mg Tolouian (DB RCT)70%0.30 · 0.05–1.78hosp.1/1876/18524mg Tolouian (DB RCT)53%0.47 · 0.25–0.87symp. case16/18734/18524mg Tolouian (DB RCT)50%0.50 · 0.24–0.99cases13/18726/18524mg
00.511.52+
1 CT: study uses combined treatment
Rotate screen for more detailsIncrease width for more details
← Bromhexine
reduces risk
Bromhexine
increases risk →
Fig. S1. All outcomes.